Research links weight loss medications like Ozempic and Zepbound to certain serious eye conditions.

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.

Weight-loss drugs such as semaglutides or tirzepatides may raise patients’ risk of nonarteritic anterior ischemic optic ...

Blockbuster GLP-1 medications like Ozempic and Mounjaro might sharpen your figure, but they could also cloud your vision in ...

A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — ...

Impact on brown adipose tissue: Berberine may lower weight by increasing brown adipose tissue, a type of fat tissue that ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

semaglutide, tirzepatide, and liraglutide. Of these three drugs, only one - semaglutide - is currently approved and offered in an oral format. It is sold by Novo Nordisk under the brand name ...

Moran Eye Center at the University of Utah have published an investigatory review of nine patients who experienced vision complications while taking popular semaglutide and tirzepatide drugs ...

Two examples of GLP-1 medications currently on the market include semaglutide and tirzepatide. Semaglutide, also known by the brand name Ozempic, first saw widespread use after trial data showed ...